ClinPGx Blog

Sign in Subscribe

Latest — Feb 25, 2026

New and Updated Antipsychotics Pathways

CPIC is currently evaluating evidence on antipsychotics and CYP2D6, CYP3A4 and CYP2C19 for the development of guidelines. To support this ClinPGx curators have expanded our set of antipsychotics pathways; updating and developing some of our in progress pathways and curating some new ones.

More issues

CPIC Guideline Update for TPMT, NUDT15 and Thiopurines

The Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2025 Update has been published in Clinical Pharmacology and Therapeutics (PMID:41618934). The guideline contains multiple updates to the previous recommendations for adjusting the starting doses of azathioprine, mercaptopurine and thioguanine according to the

New PharmCAT release

Highlights of the latest releases (v3.1.0- v3.1.1) are: * CPIC function and phenotype assignments are used to provide genotype-level guidance from all sources including DPWG and FDA. For a detailed blog see, Genotype-Phenotype Mapping for Guideline and Drug Label Curation. * Allele definitions are up to date to

Genotype-Phenotype Mapping for Guideline and Drug Label Curation

ClinPGx now uses CPIC/ClinPGx allele function and phenotype mappings and terms for guideline and drug label curation, including the interactive genotype picker tools on DPWG guideline annotation pages. If a DPWG guideline gene is not a CPIC gene, then we will continue to use DPWG mappings based on documents

Updated FDA-approved label for Xeloda (capecitabine)

The FDA-approved label for Xeloda (capecitabine) was updated a week ago to include a boxed warning regarding adverse reactions in patients with complete DPD deficiency and to "Test patients for genetic variants of DPYD prior to initiating XELODA unless immediate treatment is necessary." This language is new. The

CPIC Guideline for NAT2 Genotype and Hydralazine Therapy

The CPIC Guideline for NAT2 Genotype and Hydralazine Therapy has been published in the journal Clinical Pharmacology and Therapeutics. This new guideline summarizes and evaluates literature evidence regarding the impact of genetic variants on NAT2's metabolism of hydralazine, a vasodilator typically used in the treatment of resistant hypertension

ClinGen Pharmacogenomics Interpretation Committee Publication on Survey Findings

We are excited to announce the publication of Toward an integrated resource for pharmacogenomics (PGx): Survey findings from the genomic medicine communities (PMID: 40662343) by the ClinGen Pharmacogenomics Interpretation Committee (PGxIC) in Genetics in Medicine. This publication covers the results of the PGxIC’s two needs assessment surveys targeting both

Announcing ClinPGx

We are excited to announce the official launch of the ClinPGx website! ClinPGx brings together trusted pharmacogenomics tools and resources, presented in an easy-to-navigate format. If you're familiar with PharmGKB, you'll find improved organization of the same reliable information, and some extra features. A short video

In Press: Survey Findings on Integrating Pharmacogenomics into Genomic Medicine

We’re excited to announce that our latest paper, titled “Towards an Integrated Resource for Pharmacogenomics (PGx): Survey Findings from the Genomic Medicine Communities,” is now in press in Genetics in Medicine! This work, conducted by the ClinGen Pharmacogenomics Interpretation Committee (PGxIC, formerly the PGx Working Group), presents findings from

PharmGKB is moving to ClinPGx

Nearly two years ago, we introduced the vision for ClinPGx to integrate the PharmGKB, CPIC and PharmCAT projects into a unified resource. In June 2024, we launched the ClinPGx blog and held the first ClinPGx Meeting. We are excited to announce that over the coming weeks, PharmGKB will officially become